Cytokinetics (NASDAQ:CYTK) used its presentation at the Leerink Global Healthcare Conference to outline its transition from a long-running research-focused company into a commercial-stage ...
Cytokinetics (NASDAQ:CYTK) used its presentation at Citi’s Life Sciences Conference to highlight the recent U.S. approval of its first drug, Myqorzo, and to preview an upcoming Phase 3 readout in non- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results